Key result
ACEIs cut all-cause mortality ~11% vs. placebo in non-heart failure patients, whereas ARBs show no benefit.
Why the study?
Do ACE inhibitors and ARBs reduce all-cause mortality, cardiovascular mortality, nonfatal myocardial infarction, and stroke compared to placebo in high-risk cardiovascular patients without heart failure?
Meta-Analysis (n=77,633)
Blinded to participant, researcher, caregiver, and outcome assessor
Prospective, randomized, placebo-controlled trials
Yes
Do ACE inhibitors and ARBs reduce all-cause mortality, cardiovascular mortality, nonfatal myocardial infarction, and stroke compared to placebo in high-risk cardiovascular patients without heart failure?
In high-risk cardiovascular patients without heart failure, ACEIs significantly reduce total mortality, cardiovascular mortality, nonfatal MI, and stroke, whereas ARBs only modestly reduce stroke and should be reserved for ACEI-intolerant patients.
Answers are grounded in this paper and cite their sources.
Supports ACEI preference over ARBs for mortality reduction in high-risk patients without heart failure; challenges assumed class equivalence in cardiovascular protection.
Context. Whether angiotensin converting-enzyme inhibitors (ACEI) and angiotensin-receptor blockers (ARB) are useful in high risk patients without heart failure is unclear. We perform a meta-analysis of prospective randomized placebo-controlled ACEI or ARB trials studying patients with a combination of risk factors to assess treatment impact on all cause mortality, cardiovascular mortality, nonfatal myocardial infarction (MI) and stroke. Method. A PubMed search was made for placebo-controlled trials recruiting at least 1,200 high risk patients randomized to either ACEI or ARB, with follow-up of at least 2 years. Meta-analysis was performed using the RevMan 5 program and Mantel-Haenszel analysis was done with a fixed effects model. Results. Ten trials recruiting 77,633 patients were reviewed. All cause mortality was significantly reduced by ACEI (RR 0.89; P = 0.0008), but not by ARB treatment (RR 1.00; P = 0.89). Cardiovascular mortality and nonfatal MI were also reduced in the ACEI trials but not with ARB therapy. Stroke was significantly reduced in the ACEI trials (RR 0.75; P < 0.00001) and more modestly reduced in the ARB trials (RR 0.90; P = 0.01). Conclusion. ACEI treatment reduced stroke, nonfatal MI, cardiovascular and total mortality in high risk patients, while ARB modestly reduced stroke with no effect on nonfatal MI, cardiovascular and total mortality.
No takes yet. Share an insight, caveat, or question.
Ong et al. (2013) conducted a meta-analysis in Patients at high risk of cardiovascular events with normal left ventricular systolic function (n=77,633). Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) vs. Placebo was evaluated on All-cause mortality (ACEI vs placebo) (RR 0.89, 95% CI 0.84-0.95, p=0.0008). ACEI therapy reduced all-cause mortality compared to placebo in high-risk cardiovascular patients without heart failure, whereas ARB therapy did not.
Synapse has enriched 10 related papers. Consider them for comparative context: